Who it is for
Larger medtech and diagnostics companies
Market-access maps per country and step: MDR and IVDR, radiation protection, HTA, EHDS, plus the national extra layers (for example the Dutch screening permit regime or German genetic testing law). Change alerts through the existing webhook listener.
Startups
Where EU-recommended care is not yet implemented nationally (unmet demand), which peer country already does it, and which national rule to plan for before a pilot.
Insurers and claims handlers
Faster checks of cross-border diagnostic claims: Directive 2011/24/EU or S2 route, prior authorisation likelihood, required documents and national rules that commonly make a claim fail.
Researchers
Procedure crosswalks with a citable id, so patient pathways can be compared across countries in published studies.
Connect
Endpoint (Streamable HTTP, JSON responses, read-only): /mcp/medtech. The patient and academic server stays at /mcp.
Tools
| Tool | What it returns |
|---|---|
| Loading… | |
The same answers over REST
| Question | Endpoint |
|---|---|
| Market access for a step | /api/market-access?concept=oncology.dx.biomarker |
| Cross-border claim check | /api/claim-check?concept=oncology.dx.imaging.pet_ct&from=RO&to=DE |
| Two-way gap audit | /api/gaps?jurisdiction=NL&direction=national_to_eu |
| Research crosswalk | /api/translate?concept=oncology.dx.screening&from=RO&to=NL |
| Knowledge graph | /api/kg.jsonld, /api/kg.ttl |
| Service terms | /api/service |
What you can rely on
- Every row names its source and carries a verification level (verified, secondary, cited unverified, needs research). Only verified rows were checked against the official text on the dataset date.
- Fetched documents are hash-chained in the audit ledger; the hand-built pathway dataset is ledgered by its SHA-256 when it loads.
- The server accepts no patient data and stores nothing about the questions asked beyond standard Cloudflare request logs.
Pricing
A pricing proposal is in preparation for three groups: larger companies, startups and insurers (subscription and usage-based options). Until it is published, the MVP is free to use under the terms, and no commercial service is offered.
Interested in early access, a pilot or research collaboration? Contact: see the terms page.